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SUSTAINED RELEASE LIPOSOMAL DRUG DELIVERY FOR TREATING OCULAR 
ANGIOGENESIS 
ABSTRACT:  
The purpose of this experiment was to develop and evaluate a sustained release liposomal drug 
delivery system for treating ocular diseases such as Diabetic Retinopathy and wet Age-related 
Macular Degeneration (AMD). These diseases are characterized by ocular angiogenesis, which is 
induced by the transcription factor vascular endothelial growth factor (VEGF). Anti-VEGF 
antibody drugs such as Avastin and Lucentis are used to treat these ocular diseases; however, due 
to their short half-life (approx. 9 days) monthly intra-vitreous injections are required which are 
expensive and have low patient compliance. To improve patient care, we are developing a 
surgical implant for the eye that releases anti-VEGF antibodies over an extended period. To 
accomplish this, we have encapsulated these antibodies drugs within liposomes, suspending 
these liposomes within a hydrogel, and injected this solution into a biodegradable polymer based 
balloon implant. A SOTAX USP IV dissolution apparatus along with UV-Vis spectrophotometry 
was used to measure in-vitro antibody release rates. Additionally a Fluorotron was used to 
measure the drug release profiles of fluorescent tagged antibodies in-vivo for balloon implants 
and direct solution injections in rabbits. These experiments are ongoing, as our goal is to reach 
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INTRODUCTION: 
Ocular angiogenesis is mediated through the release of the transcription factor vascular endothelial 
growth factor (VEGF) from the retinal Mueller cells due to prolonged hypoxic conditions. This 
transcription factor causes new blood vessels to form into the eye. These blood capillaries are 
fragile and leak blood into the eye, causing blood to pool into the vitreous, resulting in permanent 
loss of vision. Diabetic Retinopathy and wet Age-related Macular Degeneration (AMD) are the 
main diseases characterized by ocular angiogenesis. Free extracellular VEGF results in 
angiogenesis when it binds to the vascular endothelial growth factor receptor (VEGFR). These 
receptors are transmembrane proteins on endothelial cells and possess a high binding affinity and 
specificity for VEGF. When VEGF interacts with its complimentary VEGFR, the receptor alters 
its conformation, resulting in an intracellular signaling cascade that leads to the proliferation of 
endothelial cells and thus angiogenesis.  
Current therapeutic intervention for these ocular diseases is conducted by administering anti-
VEGF antibody drugs like Avastin and Lucentis which are administered as intra-vitreous injection 
into the eye. These antibody drugs have a strong binding affinity and target specificity with VEGF. 
When bound to VEGF, these antibodies prevent VEGF from interacting with its receptor, thus 
blocking angiogenesis from occurring. However, theses anti-VEGF drugs have relatively short 
half-lifes (approx. 9 days) in the vitreous, thus administering monthly injections is a necessity for 
these patients. These injections are expensive, require monthly visits, and have low patient 
compliance. To improve the quality of patient care, we are developing a sustained released drug 
delivery system that can be surgically implanted in the eye and which releases the anti-VEGF 
antibodies over an extended period of time. 
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To reach our goal, we have developed both an in vitro and in vivo drug release study. The 
antibodies are encapsulated within liposomal nanoparticles and then suspended in a viscous 
hydrogel, which is injected into a biodegradable polymer based balloon implant. The in vitro drug 
release study is conducted using a SOTAX USP IV dissolution apparatus, which is used to simulate 
the eye. The release profiles of the different formulations are determined using UV-Vis 
spectrophotometry. These devices containing the formulations are circulated in 10 mM phosphate 
buffer to simulate physiological pH and ocular circulation. A control with only protein is used for 
comparing with the test samples. Furthermore, the antibodies are fluorescent tagged, to allow us 
to specifically measure the amount of protein released over a period of time. Sample aliquots from 
each formulation are taken twice a week to observe the rate of drug release. Each aliquot was 
obtained via micropipette at 200 µl per sample. Each sample was then further diluted with 800 µl 
of phosphate buffer to create a 1 ml solution. Solutions were homogenized and ran through UV-
Vis spectrophotometry. Release rates of the protein antibodies were measured at 280 nm and the 
fluorescent tags were measured at 494 nm. Two liters of fresh phosphate buffer was made each 
month for dilutions and refilling of the SOTAX apparatus. The in vivo experiments involve 
implanting Avastin liposomes embedded hydrogels filled balloon devices into the rabbits’ eyes in 
order to determine the ocular pharmacokinetics. Additionally, direct injections containing the 
Avastin liposome embedded hydrogel solutions and non-liposome embedded Avastin solutions 
were used. The rate of drug release was measured on a weekly basis using a Fluorotron to measure 
the drug release profiles. Each rabbit’s left eye was unaltered and was used as the control, while 
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Methods: 
1. Fluorescent tagging of protein 
For easy detection of the Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) 
encapsulated within the liposomes, the proteins were labelled with fluorescein. Immunoglobulin 
G was tagged using NHS fluorescein (5,6-carboxyfluorescein succinimidyl ester). The protein (1 
mg/ml) was dissolved in 20 mM sodium phosphate buffer with 0.15 M NaCl at pH 8.5. 4.7 µL of 
15 mmol NHS-fluorescein solution in DMSO was added to the protein solution and incubated at 
room temperature for 2 hr. Unreacted NHS-fluorescein was removed by dialysis using 20 mM tris-
glycine buffer at pH 8. The non-reacted dye must be completely removed for optimal results and 
accurate determination of the fluorophore-to-protein ratio. The absorbance of the labeled protein 
at 280 nm and 488 nm was measured to calculate the protein concentration and degree of labeling.  
2. Preparation of liposomes by a modified method 
Different phospholipids and cholesterol were mixed at various molar ratios 
(PC:PE:PG:Cholesterol in ratio of 60:5:5:30, 60:10:0:30, 65:5:5:25) in a round bottom flask. To 
this, 10 ml of 2:1 ratio of methanol- chloroform mixture containing 1µM anti-oxidant was added 
to make a uniform organic phase. The solvent was removed by rotary evaporator to get a uniform 
film of lipid layer. This lipid layer was hydrated using the protein solution in a pre-determined 
concentration of cryoprotectant sugar to get a final phospholipid concentration of 10 mg/ml. The 
dispersion was sonicated for 5 min in a bath sonicator. The liposome solution was extruded around 
10 times to obtain a uniform particle size of around 200 nm. The solution was then frozen at -70oC 
for 30 min and then thawed to 40oC for 20 min. The process was repeated at least 9-10 times and 
Honors Capstone 
Alexander G. Thomas 
 Bios 499H  
 
the final sample was lyophilized after removal of excess protein using gel permeation 
chromatography. 
3. Particle size measurement: 
The particle size was measured by Dynamic light scattering (DLS) on a Brookhaven BI-200SM 
Research Goniometer and Laser Light Scattering System (5mW He–Ne laser, λ=632 nm) using 
CONTIN software. To obtain the diffusion coefficient, the intensity correlation function must be 
analyzed. The hydrodynamic diameter and the particle size distribution were generated by the 
software. Accuracy of the data was determined based on polydispersity and baseline difference 
from the correlation curve. Particle size of the samples was measured at various stages and time 
intervals as a means to determine the stability and shelf-life. 
1. Encapsulation efficiency 
The change in fluorescence signal can be used to assess the membrane permeability. The extent of 
the leakage from an encapsulated liposome due to contact with a certain solute was determined 
from the relative fluorescence (%F) of the leaked marker (fluorescent tagged IgG) and is calculated 
by equation: 
Encapsulation efficiency =   FT – F0 
                                                                    FM – F0 
where, FT – Fluorescence of liposomes after incubation with solute  
 F0 – Initial fluorescence due to dilution in an isomolar buffer  
 FM – Maximal fluorescence after lysis by Triton X-100  
2. Structural stability of protein released from liposomes: 
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Secondary structure analysis was performed by far UV CD using Aviv Circular Dichroism 
Spectrometer, model 215 with a 50 KHz photoelastic modulator. The spectra were recorded with 
0.01 cm path length quartz cuvette between 190 and 300 nm using a slit width of 1 nm and a scan 
speed of 20 nm/min.  
3. Transmission electron microscopy for imaging 
Briefly, a drop of a water-diluted suspension of the liposomes (about 0.05 mg/mL) was placed on 
a 200-mesh formvar copper grid (Electron Microscopy Sciences), allowed to adsorb and the 
surplus was removed by filter paper. A drop of 2% (w/v) aqueous solution of uranyl acetate was 
added and left in contact with the sample for 5 minutes.  The surplus water was removed and the 
sample was dried at room temperature before the vesicles were imaged with a TEM operating at 
an acceleration voltage of 200 KV. 
4. Drug release studies: 
Drug release studies were performed using USP 4 dissolution apparatus (SOTAX Corporation). 
The flow rate was maintained at 1 ml/min. Aliquots were removed at regular intervals and the 
concentration of the drug released was screened using fluorescence spectrophotometry. 
Concentration of fluorescent tagged protein released was measured using UV-Vis 
spectrophotometry. The concentration of protein in the solution was measured based on the 
absorbance from the fluorescent label using the equation: 
           Protein concentration (M) = A280 x dilution factor 
                                                                 Ɛprotein 
where, Ɛ of IgG is ~210,000 M-1 cm-1 
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5. Animal Studies: 
Two sets of Dutch belted rabbits were used as animal models for testing the liposomal 
formulations. One set of rabbits received a single 0.15 ml intravitreal injection of fluorescent 
tagged Bevacizumab and another set of rabbits received a 0.15 ml intravitreal injection of liposome 
suspension encapsulating fluorescent tagged Bevacizumab. Both sets of rabbits had a vitrectomy 
before administration of the formulations. Change in concentrations of the drug in the rabbit’s eye 
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RESULTS: 
The strategy of delivering proteins to ocular compartments using carriers represents the most 
promising approach to improve protein bioavailability. Lucentis and Avastin are given as monthly 
injections and hence increase the risk of infection. Our current study deals with the design and 
optimization of liposomes to address the problems of encapsulating proteins as well as protecting 
them from degradation. Our interest in this research project was to encapsulate the protein drug in 
our stable liposomal formulations, prolong the time of drug release into the eye, thereby, 
decreasing the frequency as well as the cost factor for these treatments. 
Fluorescein tagged Bevacizumab (Avastin) was used to study the encapsulation and drug release 
of the protein. The method we used for the encapsulation of fluorescein tagged proteins was a 
combination of lipid hydration, extrusion and mannitol freeze thaw methods. Particle size, 
encapsulation efficiency and time of release from formulations of different concentrations of 
phospholipids and cholesterol have been reported in Figure 1.  TEM images of the formulations 
containing conventional and stealth liposomes are displayed in Figures 2 and 4. The results from 
in vitro drug release studies using conventional and stealth liposomes were performed using the 
SOTAX USP 4 dissolution apparatus and the results are presented in Figures 3 and 5 respectively. 
Dutch belted rabbits were used as animal models for studying the in vivo drug release kinetics. 
Fluorescent tagged Avastin, in free solution and encapsulated within liposomes, was injected 
intravitreally into the rabbit’s eye after vitrectomy to prevent increase in the intraocular pressure. 
The release kinetics were measured on a weekly basis by scanning the rabbit’s eye using a 
Fluorotron Master spectrophotometer. The Fluorotron Master is calibrated to provide readouts of 
fluorescence from the fluorescent label on the Avastin. In the Fluorotron Master, a blue excitation 
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light is delivered through the optics of the system to the eye and the resulting emitted fluorescent 
light is collected via the same optical system. Fluorescence arbitrary units in the eye were plotted 
against distance data points separated by 0.10 mm on an optical axis. This distance in millimeters 
on the plot cannot be related to the actual dimensions of rabbit eye tissues. However, potential 
tissue assignments to data points can be made based on comparing tissue autofluorescence peaks 
and by monitoring fluorescence signal after the fluorescent marker injection in various 
compartments of the eye. Figure 6 shows representative Fluorotron scans from eyes that received 
a single 0.15 ml intravitreal injection of fluorescent tagged Bevacizumab. Results from this data 
indicate that majority of the drug injected is eliminated within 4-5 weeks.  Figure 6 shows 
representative Fluorotron scans from eyes that received a single 0.15 ml intravitreal injection of 
liposome suspension encapsulating fluorescent tagged Bevacizumab. Results from this data 
indicate the release of Avastin into the vitreous and slow diffusion towards the back of the eye 
over a period of time. 
DISCUSSION: 
Due to the short half-life of anti-VEGF antibody drugs within the eye, frequent injections have 
become common practice. This approach is costly and time consuming, and has resulted in low 
patient compliance. Additionally, such frequent injections can also lead to an increased risk of 
secondary infections. By using liposomal based drug delivery systems, these problems can be 
overcome through sustained release of the drugs over prolonged periods of time. This technology 
possesses the potential to overcome the disadvantages of the current practices and improve 
patient care as a better model for treating diseases of ocular angiogenesis.  
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Figure 1: Particle size, % encapsulation and time of release from different liposomal 
formulations 
Honors Capstone 
Alexander G. Thomas 
 Bios 499H  
 
 




Alexander G. Thomas 











Alexander G. Thomas 




Figure 4: TEM image of stealth liposomes 60:5:5:30, 65:5:5:25 and 60:10:30 with encapsulated 
Avastin 
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Figure 5: Drug release profiles of long circulating or stealth liposomes with encapsulated 
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